MX2020013649A - Composiciones y metodos para inhibir la actividad de la arginasa. - Google Patents
Composiciones y metodos para inhibir la actividad de la arginasa.Info
- Publication number
- MX2020013649A MX2020013649A MX2020013649A MX2020013649A MX2020013649A MX 2020013649 A MX2020013649 A MX 2020013649A MX 2020013649 A MX2020013649 A MX 2020013649A MX 2020013649 A MX2020013649 A MX 2020013649A MX 2020013649 A MX2020013649 A MX 2020013649A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compositions
- arginase activity
- inhibiting arginase
- disclosure
- Prior art date
Links
- 102000004452 Arginase Human genes 0.000 title abstract 3
- 108700024123 Arginases Proteins 0.000 title abstract 3
- 230000000694 effects Effects 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La descripción se refiere a una clase novedosa de compuestos que muestran actividad inhibitoria hacia la arginasa, y composiciones farmaceúticas que comprenden los compuestos de la descripción. En la presente también se proporcionan métodos de tratamiento contra el cáncer con los inhibidores de la arginasa de la descripción.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662438092P | 2016-12-22 | 2016-12-22 | |
| US201662439614P | 2016-12-28 | 2016-12-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020013649A true MX2020013649A (es) | 2021-02-26 |
Family
ID=60972528
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019007471A MX378460B (es) | 2016-12-22 | 2017-12-22 | Composiciones y métodos para inhibir la actividad de la arginasa. |
| MX2020013649A MX2020013649A (es) | 2016-12-22 | 2019-06-20 | Composiciones y metodos para inhibir la actividad de la arginasa. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019007471A MX378460B (es) | 2016-12-22 | 2017-12-22 | Composiciones y métodos para inhibir la actividad de la arginasa. |
Country Status (33)
| Country | Link |
|---|---|
| US (4) | US10287303B2 (es) |
| EP (2) | EP3559009B1 (es) |
| JP (2) | JP7018949B2 (es) |
| KR (1) | KR102579849B1 (es) |
| CN (2) | CN110382508B (es) |
| AU (2) | AU2017382405B2 (es) |
| BR (1) | BR112019012589B1 (es) |
| CA (1) | CA3046987A1 (es) |
| CL (1) | CL2019001711A1 (es) |
| CO (1) | CO2019007839A2 (es) |
| CR (1) | CR20190339A (es) |
| CY (1) | CY1124483T1 (es) |
| DK (2) | DK3559009T3 (es) |
| EC (1) | ECSP19045511A (es) |
| ES (2) | ES2881395T3 (es) |
| HR (1) | HRP20210848T1 (es) |
| HU (1) | HUE054272T2 (es) |
| IL (2) | IL292677A (es) |
| LT (1) | LT3559009T (es) |
| MD (1) | MD3559009T2 (es) |
| MX (2) | MX378460B (es) |
| MY (1) | MY197478A (es) |
| NZ (1) | NZ754364A (es) |
| PE (1) | PE20191541A1 (es) |
| PH (1) | PH12019501396A1 (es) |
| PL (1) | PL3559009T3 (es) |
| PT (1) | PT3559009T (es) |
| RS (1) | RS61996B1 (es) |
| SG (2) | SG10201911243WA (es) |
| SI (1) | SI3559009T1 (es) |
| SM (1) | SMT202100573T1 (es) |
| TW (1) | TWI818902B (es) |
| WO (1) | WO2018119440A1 (es) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5909239B2 (ja) | 2010-10-26 | 2016-04-26 | マーズ インコーポレイテッド | アルギナーゼ阻害剤としてのボロネート |
| TW201718581A (zh) | 2015-10-19 | 2017-06-01 | 英塞特公司 | 作為免疫調節劑之雜環化合物 |
| SMT202200369T1 (it) | 2015-11-19 | 2022-11-18 | Incyte Corp | Composti eterociclici come immunomodulatori |
| MA44075A (fr) | 2015-12-17 | 2021-05-19 | Incyte Corp | Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1 |
| SG10202005790VA (en) | 2015-12-22 | 2020-07-29 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| ES2906460T3 (es) | 2016-05-06 | 2022-04-18 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| TW201808902A (zh) | 2016-05-26 | 2018-03-16 | 美商英塞特公司 | 作為免疫調節劑之雜環化合物 |
| SG11201811414TA (en) | 2016-06-20 | 2019-01-30 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| MA45669A (fr) | 2016-07-14 | 2019-05-22 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| MA46045A (fr) | 2016-08-29 | 2021-04-28 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| WO2018119236A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
| PL3558990T3 (pl) * | 2016-12-22 | 2022-12-19 | Incyte Corporation | Pochodne tetrahydroimidazo[4,5-c]pirydyny jako induktory internalizacji pd-l1 |
| MX391981B (es) | 2016-12-22 | 2025-03-21 | Incyte Corp | Derivados de benzooxazol como inmunomoduladores. |
| US20180179179A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| MX378460B (es) * | 2016-12-22 | 2025-03-10 | Calithera Biosciences Inc | Composiciones y métodos para inhibir la actividad de la arginasa. |
| MA47099A (fr) | 2016-12-22 | 2021-05-12 | Incyte Corp | Composés hétéroaromatiques bicycliques utilisés en tant qu'immunomodulateurs |
| CN108322295B (zh) | 2017-01-17 | 2021-12-24 | 维沃移动通信有限公司 | 一种边带信息的发送方法、接收方法、发送端和接收端 |
| CN117186134A (zh) | 2018-02-17 | 2023-12-08 | 阿斯利康(瑞典)有限公司 | 精氨酸酶抑制剂及其使用方法 |
| TWI723366B (zh) | 2018-03-29 | 2021-04-01 | 波蘭商昂科艾倫迪治療法股份公司 | 二肽哌啶衍生物 |
| UA128453C2 (uk) | 2018-03-30 | 2024-07-17 | Інсайт Корпорейшн | Гетероциклічні сполуки як імуномодулятори |
| PL3790877T3 (pl) | 2018-05-11 | 2023-06-12 | Incyte Corporation | Pochodne tetrahydroimidazo[4,5-c]pirydyny jako immunomodulatory pd-l1 |
| CN112584900B (zh) | 2018-08-22 | 2025-07-15 | 阿斯利康(瑞典)有限公司 | 精氨酸酶抑制剂及其使用方法 |
| US12240867B2 (en) | 2018-12-18 | 2025-03-04 | Merck Sharp & Dohme Llc | Arginase inhibitors and methods of use |
| EA202192114A1 (ru) * | 2019-02-08 | 2021-12-01 | Астразенека Аб | Ингибиторы аргиназы и способы их применения |
| WO2021030162A1 (en) | 2019-08-09 | 2021-02-18 | Incyte Corporation | Salts of a pd-1/pd-l1 inhibitor |
| CN110759843A (zh) * | 2019-09-30 | 2020-02-07 | 东北师范大学 | 一种氟叠氮取代的四元杂环化合物的制备和应用 |
| CN115175734B (zh) | 2019-09-30 | 2024-04-19 | 因赛特公司 | 作为免疫调节剂的吡啶并[3,2-d]嘧啶化合物 |
| CN110734456A (zh) * | 2019-11-06 | 2020-01-31 | 南京谷睿生物科技有限公司 | 一种化合物及其制备方法和医药上的应用 |
| CA3160131A1 (en) | 2019-11-11 | 2021-05-20 | Incyte Corporation | Salts and crystalline forms of a pd-1/pd-l1 inhibitor |
| WO2021257857A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Naphthyridinone compounds as jak2 v617f inhibitors |
| US11753413B2 (en) | 2020-06-19 | 2023-09-12 | Incyte Corporation | Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors |
| WO2022006456A1 (en) | 2020-07-02 | 2022-01-06 | Incyte Corporation | Tricyclic pyridone compounds as jak2 v617f inhibitors |
| CA3188639A1 (en) | 2020-07-02 | 2022-01-06 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
| TW202216662A (zh) | 2020-07-17 | 2022-05-01 | 美商英塞特公司 | 製備精胺酸酶抑制劑及其合成中間物之方法 |
| WO2022046989A1 (en) | 2020-08-27 | 2022-03-03 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
| WO2022099018A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process of preparing a pd-1/pd-l1 inhibitor |
| US11760756B2 (en) | 2020-11-06 | 2023-09-19 | Incyte Corporation | Crystalline form of a PD-1/PD-L1 inhibitor |
| MX2023005362A (es) | 2020-11-06 | 2023-06-22 | Incyte Corp | Proceso para hacer un inhibidor de proteina de muerte programada 1 (pd-1)/ligando de muerte programada 1 (pd-l1) y sales y formas cristalinas del mismo. |
| CN112387262B (zh) * | 2020-11-10 | 2021-12-07 | 泰州学院 | 一种基于光催化交联蛋白的手性固定相的制备方法、手性固定相及应用 |
| US11919908B2 (en) | 2020-12-21 | 2024-03-05 | Incyte Corporation | Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors |
| TW202228720A (zh) | 2020-12-22 | 2022-08-01 | 波蘭商昂科艾倫迪治療法股份公司 | 精胺酸酶抑制劑及其使用方法 |
| EP4298099A1 (en) | 2021-02-25 | 2024-01-03 | Incyte Corporation | Spirocyclic lactams as jak2 v617f inhibitors |
| WO2023133505A2 (en) * | 2022-01-07 | 2023-07-13 | The Trustees Of Columbia University In The City Of New York | Inhibition of kynurenine synthesis and/or signaling to treat leukemia and myelodysplasia |
| JP2025509672A (ja) | 2022-03-17 | 2025-04-11 | インサイト・コーポレイション | Ｊａｋ２ ｖ６１７ｆ阻害剤としての三環式尿素化合物 |
| TW202416968A (zh) | 2022-10-21 | 2024-05-01 | 美商英塞特公司 | 作為ｊａｋ２ ｖ６１７ｆ抑制劑之三環脲化合物 |
| AU2024237095A1 (en) | 2023-03-13 | 2025-09-25 | Incyte Corporation | Bicyclic ureas as kinase inhibitors |
Family Cites Families (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
| GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
| US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
| US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
| ES2206965T3 (es) | 1997-07-29 | 2004-05-16 | Alcon Laboratories, Inc. | Composiciones oftalmicas que contienen polimeros de galactomanana y borato. |
| EP1049660A1 (en) | 1997-10-10 | 2000-11-08 | The Trustees Of The University Of Pennsylvania | Compositions and methods for inhibiting arginase activity |
| US6110973A (en) | 1998-01-29 | 2000-08-29 | Sepracor | Methods for treating obesity and weight gain using optically pure (-)-bupropion |
| US20040063666A1 (en) | 1998-10-09 | 2004-04-01 | David Christianson | Compositions for inhibiting arginase activity |
| US8889112B2 (en) | 1999-09-16 | 2014-11-18 | Ocularis Pharma, Llc | Ophthalmic formulations including selective alpha 1 antagonists |
| ATE536375T1 (de) | 2000-05-10 | 2011-12-15 | Mayo Foundation | Menschliche igm antikörper, welche die fähigkeit besitzen, den wiederaufbau der myelinstruktur zu induzieren und deren diagnostische und therapeutische anwendung im zentralen nervensystem |
| WO2002004465A1 (en) | 2000-07-06 | 2002-01-17 | Fal Diagnostics | Methods and kits for the detection of arginine compounds |
| CA2431080A1 (en) | 2003-06-02 | 2004-12-02 | Catherine Adele O'brien | Enhancement of anticancer immunity through inhibition of arginase |
| US6933289B2 (en) | 2003-07-01 | 2005-08-23 | Allergan, Inc. | Inhibition of irritating side effects associated with use of a topical ophthalmic medication |
| EP1654002B2 (en) | 2003-08-07 | 2014-01-29 | Allergan, Inc. | Compositions for delivery of therapeutics into the eyes |
| US20050059744A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| EP1915143A4 (en) | 2005-07-01 | 2009-11-11 | Univ Johns Hopkins | ARGINASE II: TARGET TREATMENT FOR THE AGING HEART AND HEART FAILURE |
| WO2007095050A2 (en) | 2006-02-09 | 2007-08-23 | Incyte Corporation | N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase |
| WO2008036643A2 (en) | 2006-09-19 | 2008-03-27 | Incyte Corporation | Amidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| CA2663057C (en) | 2006-09-19 | 2015-12-08 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| US20080146624A1 (en) | 2006-09-19 | 2008-06-19 | Incyte Corporation | Amidines as modulators of indoleamine 2,3-dioxygenase |
| US20080182882A1 (en) | 2006-11-08 | 2008-07-31 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| MX2009005370A (es) | 2006-11-21 | 2009-10-16 | Univ Groningen | Uso de inhibidores de arginasa en el tratamiento de asma y rinitis alergica. |
| CN103288833B (zh) | 2006-11-22 | 2018-01-12 | 因塞特控股公司 | 作为激酶抑制剂的咪唑并三嗪和咪唑并嘧啶 |
| US20100189544A1 (en) | 2007-07-12 | 2010-07-29 | Sanyo Denki Co., Ltd. | Counter-rotating axial-flow fan |
| CN103191129A (zh) | 2007-10-12 | 2013-07-10 | C.T.辨析有限公司 | 治疗眼睛病症的脂氧化物类化合物 |
| CA2932121A1 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics Corporation | Ido inhibitors |
| WO2011116299A2 (en) | 2010-03-18 | 2011-09-22 | Colorado State University Research Foundation | Myeloid derived suppressor cell inhibiting agents |
| WO2009132238A2 (en) | 2008-04-24 | 2009-10-29 | Newlink Genetics | Ido inhibitors |
| WO2009137378A2 (en) | 2008-05-05 | 2009-11-12 | Schering Corporation | Sequential administration of chemotherapeutic agents for treatment of cancer |
| BR122019015876B8 (pt) | 2008-07-08 | 2021-07-27 | Incyte Holdings Corp | compostos derivados de 1,2,5-oxadiazóis, composição, bem como seus usos |
| DK2389352T3 (da) | 2009-01-26 | 2019-07-29 | Univ Pennsylvania | Arginaseinhibitorer og anvendelsesfremgangsmåder |
| AU2010339508B2 (en) | 2009-12-31 | 2016-02-04 | Innocrin Pharmaceuticals, Inc. | Metalloenzyme inhibitor compounds |
| NZ603364A (en) | 2010-04-22 | 2015-06-26 | Mars Inc | Inhibitors of arginase and their therapeutic applications |
| EP2563771B1 (en) | 2010-04-24 | 2015-11-25 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitor compounds |
| SG187757A1 (en) | 2010-08-10 | 2013-03-28 | Rempex Pharmaceuticals Inc | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
| MX2013002198A (es) | 2010-08-27 | 2013-03-18 | Merck Patent Gmbh | Derivados de triazolopirazina. |
| JP5909239B2 (ja) | 2010-10-26 | 2016-04-26 | マーズ インコーポレイテッド | アルギナーゼ阻害剤としてのボロネート |
| JP5921560B2 (ja) | 2010-10-28 | 2016-05-24 | イノクリン ファーマシューティカルズ，インコーポレイテッド | 金属酵素阻害化合物 |
| CA2817691C (en) | 2010-11-13 | 2020-09-01 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitor compounds |
| CN103328452A (zh) | 2010-12-13 | 2013-09-25 | 威尔金制药有限公司 | 金属酶抑制剂化合物 |
| CN104857005B (zh) | 2010-12-31 | 2019-04-26 | 阿斯利康公司 | 精氨酸酶抑制剂及其使用方法 |
| NO2694640T3 (es) | 2011-04-15 | 2018-03-17 | ||
| EP2721021B1 (en) | 2011-06-19 | 2019-01-23 | Viamet Pharmaceuticals (NC), Inc. | Metalloenzyme inhibitor compounds |
| CA2838912C (en) | 2011-06-19 | 2019-11-26 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitor compounds |
| WO2012177728A1 (en) | 2011-06-23 | 2012-12-27 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitor compounds |
| AU2012300275A1 (en) | 2011-08-30 | 2014-03-06 | Innocrin Pharmaceuticals, Inc. | Metalloenzyme inhibitor compounds |
| WO2013059437A1 (en) | 2011-10-19 | 2013-04-25 | Mars, Incorporated | Inhibitors of arginase and their therapeutic applications |
| ES2627347T3 (es) * | 2011-10-20 | 2017-07-27 | Glaxosmithkline Llc | Aza-heterociclos bicíclicos sustituidos y análogos como moduladores de sirtuina |
| CN104203936B (zh) | 2011-12-11 | 2017-04-19 | 威尔金制药有限公司 | 金属酶抑制剂化合物 |
| ES2774267T3 (es) | 2012-01-20 | 2020-07-20 | Mycovia Pharmaceuticals Inc | Compuestos inhibidores de metaloenzimas |
| EP2807161B1 (en) | 2012-01-28 | 2017-10-04 | Merck Patent GmbH | Triazolo[4,5-d]pyrimidine derivatives |
| EP2817310B1 (en) | 2012-02-21 | 2018-03-21 | Merck Patent GmbH | 8-substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrazines as syk tryrosine kinase inhibitors and gcn2 serin kinase inhibitors |
| CA2865040C (en) | 2012-02-21 | 2020-07-14 | Merck Patent Gmbh | Cyclic diaminopyrimidine derivatives |
| CA2866450C (en) | 2012-03-07 | 2020-02-18 | Merck Patent Gmbh | Triazolopyrazine derivatives |
| EP2852598B3 (en) | 2012-04-18 | 2016-10-19 | Mars, Incorporated | Ring constrained analogs as arginase inhibitors |
| CA2881279C (en) | 2012-08-07 | 2020-07-07 | Merck Patent Gmbh | Pyridopyrimidine derivatives as protein kinase inhibitors |
| US20150246898A1 (en) | 2012-09-12 | 2015-09-03 | Dow Agrosciences Llc | Metalloenzyme inhibitor compounds |
| EP2914263A4 (en) | 2012-11-02 | 2016-04-27 | Pharmacyclics Inc | ADJUVANT THERAPY WITH TEC FAMILY KINASE INHIBITOR |
| EP2948450A4 (en) | 2013-01-28 | 2016-11-09 | Viamet Pharmaceuticals Inc | METALLOENZYMINHIBITORVERBINDUNGEN |
| AU2014224975B2 (en) | 2013-03-05 | 2017-09-14 | Merck Patent Gmbh | Triazolo(4,5-d)pyrimidine derivatives for the treatment of diseases such as cancer |
| EP2964648B1 (en) | 2013-03-05 | 2016-11-16 | Merck Patent GmbH | 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents |
| EP2976332B1 (en) | 2013-03-14 | 2018-01-31 | Newlink Genetics Corporation | Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization. |
| WO2014186035A1 (en) | 2013-03-14 | 2014-11-20 | Curadev Pharma Private Ltd. | Inhibitors of the kynurenine pathway |
| WO2014141110A2 (en) | 2013-03-14 | 2014-09-18 | Curadev Pharma Pvt. Ltd. | Aminonitriles as kynurenine pathway inhibitors |
| JP6313415B2 (ja) | 2013-03-15 | 2018-04-18 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｉｄｏ阻害剤 |
| CN105209443B (zh) | 2013-03-15 | 2018-08-07 | 百时美施贵宝公司 | 吲哚胺2,3-双加氧酶(ido)抑制剂 |
| US9861635B2 (en) | 2013-05-06 | 2018-01-09 | Merck Patent Gmbh | Macrocycles as kinase inhibitors |
| HK1223093A1 (zh) | 2013-05-28 | 2017-07-21 | Viamet Pharmaceuticals (NC), Inc. | 杀真菌组合物 |
| CA2916615A1 (en) | 2013-07-01 | 2015-01-08 | Bristol-Myers Squibb Company | Ido inhibitors |
| JP6478991B2 (ja) | 2013-07-11 | 2019-03-06 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｉｄｏ阻害剤 |
| US10821178B2 (en) | 2013-07-29 | 2020-11-03 | Board Of Regents Of The University Of Nebraska | Methods of treating biofilm infections comprising administering inhibitors of myeloid-derived suppressor cells |
| MX2016002075A (es) | 2013-08-27 | 2016-05-26 | Squibb Bristol Myers Co | Inhibidores de indolamina 2,3-dioxigenasa (ido). |
| AU2014339816B2 (en) | 2013-10-25 | 2020-05-28 | Pharmacyclics Llc | Treatment using Bruton's tyrosine kinase inhibitors and immunotherapy |
| DK3066085T3 (da) | 2013-11-08 | 2020-06-02 | Incyte Holdings Corp | Fremgangsmåde til syntesen af en indolamin-2,3-dioxygenaseinhibitor |
| SG11201606428UA (en) | 2014-02-04 | 2016-09-29 | Incyte Corp | Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer |
| WO2015160664A1 (en) | 2014-04-15 | 2015-10-22 | Dow Agrosciences Llc | Metalloenzyme inhibitor compounds as fungicides |
| US9944664B2 (en) | 2014-04-15 | 2018-04-17 | Dow Agrosciences Llc | Metalloenzyme inhibitor compounds as fungicides |
| RU2016149812A (ru) | 2014-06-06 | 2018-07-17 | Флексус Байосайенсиз, Инк. | Иммунорегулирующие средства |
| TW201619133A (zh) | 2014-08-21 | 2016-06-01 | 裘拉德製藥私人有限公司 | 新穎亞氨腈（ｉｍｉｎｏｎｉｔｒｉｌｅ）衍生物 |
| CA2956465A1 (en) | 2014-09-05 | 2016-03-10 | Merck Patent Gmbh | Cyclohexyl-ethyl substituted diaza- and triaza-tricyclic compounds as indole-amine-2,3-dioxygenase (ido) antagonists for the treatment of cancer |
| CN105879030A (zh) | 2014-09-30 | 2016-08-24 | 复旦大学 | 治疗肿瘤的增效药物复合物及其制备方法 |
| GB201417369D0 (en) | 2014-10-01 | 2014-11-12 | Redx Pharma Ltd | Compounds |
| WO2016057986A1 (en) | 2014-10-10 | 2016-04-14 | The Trustees Of Columbia University In The City Of New York | Tandem epitope constructs for presentation of cd4 and cd8 epitopes and uses thereof |
| GB201418300D0 (en) | 2014-10-15 | 2014-11-26 | Redx Pharma Ltd | Compounds |
| CA2964276A1 (en) | 2014-11-05 | 2016-05-12 | Flexus Biosciences, Inc. | Immunoregulatory agents |
| UY36390A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen |
| AR102537A1 (es) | 2014-11-05 | 2017-03-08 | Flexus Biosciences Inc | Agentes inmunomoduladores |
| WO2016130501A1 (en) | 2015-02-09 | 2016-08-18 | Incyte Corporation | Aza-heteroaryl compounds as pi3k-gamma inhibitors |
| KR20170129896A (ko) | 2015-03-20 | 2017-11-27 | 새미 오유 오피요 | 악성 신생물에 대한 수라민 및 아르기나아제 억제제의 용도 |
| HK1247922A1 (zh) | 2015-04-03 | 2018-10-05 | Bristol-Myers Squibb Company | 用於治疗癌症的吲哚胺2，3-双加氧酶抑制剂 |
| MA51438A (fr) | 2015-04-03 | 2021-04-14 | Incyte Corp | Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1 |
| WO2016181348A1 (en) | 2015-05-14 | 2016-11-17 | Pfizer Inc. | Combinations comprising a pyrrolidine-2,5-dione ido1 inhibitor and an anti-body |
| WO2016196890A1 (en) | 2015-06-04 | 2016-12-08 | Vtv Therapeutics Llc | Inhibitors of hexokinase and methods of use thereof |
| MA42269A (fr) | 2015-06-23 | 2018-05-02 | Calithera Biosciences Inc | Compositions et procédés d'inhibition de l'activité de l'arginase |
| ES2808988T3 (es) | 2015-10-30 | 2021-03-02 | Calithera Biosciences Inc | Composiciones y métodos para inhibir la actividad arginasa |
| PL417066A1 (pl) | 2016-05-04 | 2017-11-06 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory arginazy oraz ich zastosowania terapeutyczne |
| MX378460B (es) | 2016-12-22 | 2025-03-10 | Calithera Biosciences Inc | Composiciones y métodos para inhibir la actividad de la arginasa. |
| MX2019013533A (es) | 2017-05-12 | 2020-08-03 | Calithera Biosciences Inc | Metodo para preparar (3r,4s)-3-acetamido-4-alil-n-(terc-butil)pirr olidina-3-carboxamida. |
-
2017
- 2017-12-22 MX MX2019007471A patent/MX378460B/es unknown
- 2017-12-22 BR BR112019012589-2A patent/BR112019012589B1/pt not_active IP Right Cessation
- 2017-12-22 SM SM20210573T patent/SMT202100573T1/it unknown
- 2017-12-22 CA CA3046987A patent/CA3046987A1/en active Pending
- 2017-12-22 MY MYPI2019003368A patent/MY197478A/en unknown
- 2017-12-22 PE PE2019001311A patent/PE20191541A1/es unknown
- 2017-12-22 US US15/853,310 patent/US10287303B2/en active Active
- 2017-12-22 SG SG10201911243WA patent/SG10201911243WA/en unknown
- 2017-12-22 WO PCT/US2017/068307 patent/WO2018119440A1/en not_active Ceased
- 2017-12-22 AU AU2017382405A patent/AU2017382405B2/en not_active Ceased
- 2017-12-22 HR HRP20210848TT patent/HRP20210848T1/hr unknown
- 2017-12-22 KR KR1020197021468A patent/KR102579849B1/ko active Active
- 2017-12-22 HU HUE17829574A patent/HUE054272T2/hu unknown
- 2017-12-22 EP EP17829574.7A patent/EP3559009B1/en active Active
- 2017-12-22 CN CN201780080358.1A patent/CN110382508B/zh active Active
- 2017-12-22 ES ES17829574T patent/ES2881395T3/es active Active
- 2017-12-22 RS RS20210763A patent/RS61996B1/sr unknown
- 2017-12-22 PT PT178295747T patent/PT3559009T/pt unknown
- 2017-12-22 EP EP21158664.9A patent/EP3842442B1/en active Active
- 2017-12-22 LT LTEP17829574.7T patent/LT3559009T/lt unknown
- 2017-12-22 DK DK17829574.7T patent/DK3559009T3/da active
- 2017-12-22 DK DK21158664.9T patent/DK3842442T3/da active
- 2017-12-22 CN CN202210836886.8A patent/CN114989205A/zh active Pending
- 2017-12-22 ES ES21158664T patent/ES2970715T3/es active Active
- 2017-12-22 IL IL292677A patent/IL292677A/en unknown
- 2017-12-22 TW TW106145440A patent/TWI818902B/zh active
- 2017-12-22 MD MDE20191232T patent/MD3559009T2/ro unknown
- 2017-12-22 CR CR20190339A patent/CR20190339A/es unknown
- 2017-12-22 SG SG10201911240PA patent/SG10201911240PA/en unknown
- 2017-12-22 JP JP2019534159A patent/JP7018949B2/ja active Active
- 2017-12-22 SI SI201730835T patent/SI3559009T1/sl unknown
- 2017-12-22 PL PL17829574T patent/PL3559009T3/pl unknown
- 2017-12-22 NZ NZ754364A patent/NZ754364A/en not_active IP Right Cessation
-
2019
- 2019-03-29 US US16/370,857 patent/US10597411B2/en not_active Expired - Fee Related
- 2019-06-18 PH PH12019501396A patent/PH12019501396A1/en unknown
- 2019-06-19 CL CL2019001711A patent/CL2019001711A1/es unknown
- 2019-06-20 MX MX2020013649A patent/MX2020013649A/es unknown
- 2019-06-20 IL IL267532A patent/IL267532B/en unknown
- 2019-06-26 EC ECSENADI201945511A patent/ECSP19045511A/es unknown
- 2019-07-22 CO CONC2019/0007839A patent/CO2019007839A2/es unknown
-
2020
- 2020-02-14 US US16/792,186 patent/US11021495B2/en active Active
-
2021
- 2021-01-20 US US17/153,804 patent/US12054501B2/en active Active
- 2021-07-05 CY CY20211100602T patent/CY1124483T1/el unknown
-
2022
- 2022-02-01 JP JP2022014021A patent/JP2022066199A/ja not_active Abandoned
- 2022-02-17 AU AU2022201072A patent/AU2022201072A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020013649A (es) | Composiciones y metodos para inhibir la actividad de la arginasa. | |
| MY201783A (en) | Compositions and methods for inhibiting arginase activity | |
| PH12016502179A1 (en) | Inhibitors of lysine specific demethylase-1 | |
| PH12015502028A1 (en) | Ido inhibitors | |
| MY199705A (en) | Heterocyclic compounds as immunomodulators | |
| PH12018501084A1 (en) | Heterocyclic compounds as immunomodulators | |
| MX384792B (es) | Inhibidores de desmetilasa especifica de lisina 1 (lsd1). | |
| MX2016000295A (es) | Inhibidores de indoleamina 2,3-dioxigenasa (ido). | |
| MX2016002075A (es) | Inhibidores de indolamina 2,3-dioxigenasa (ido). | |
| EA033395B1 (ru) | Ингибиторы индоламин-2,3-диоксигеназы и способы их применения | |
| MX2015011374A (es) | Inhibidores de indolamina 2,3-dioxigenasa (ido). | |
| MX2015017486A (es) | Inhibidores de indolamina 2,3-dioxigenasa (dio). | |
| SA519410093B1 (ar) | مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز | |
| PH12016501462A1 (en) | Neprilysin inhibitors | |
| AU2015299431B2 (en) | Pyrrolidinone derivatives as metAP-2 inhibitors | |
| MX394452B (es) | Inhibicion de la actividad de olig2. | |
| PH12017500459A1 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
| ZA201901367B (en) | Inhibition of olig2 activity | |
| EA201991517A1 (ru) | Композиции и способы ингибирования активности аргиназы | |
| WO2017023684A3 (en) | Covalent irreversible inhibitors of usp7 as anti-cancer agents | |
| EA202191138A1 (ru) | Композиции и способы для ингибирования активности аргиназы | |
| GB2553684A8 (en) | Ethynylxanthines, preparation and use for cancer treatment |